<DOC>
	<DOCNO>NCT01533155</DOCNO>
	<brief_summary>Study healthy volunteer investigate effect Quinidine Pharmacokinetics NKTR-118</brief_summary>
	<brief_title>Study Healthy Volunteers Investigate Effects Quinidine Pharmacokinetics NKTR-118</brief_title>
	<detailed_description>A Randomized , 2-Part , Crossover , Single Center Study Evaluate Effect Quinidine Pharmacokinetics NKTR-118 Concomitant Effect Quinidine NKTR-118 Morphine-induced Miosis</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<criteria>Provision sign date , write informed consent prior studyspecific procedure . Male female ( nonchildbearing potential , nonlactating ) healthy volunteer age 18 55 year inclusive , suitable vein cannulation repeat venipuncture . Female volunteer must nonpregnant nonlactating . Women childbearing potential must negative pregnancy test ( screen admission ) use highlyeffective form birth control 3 month enrollment . Male volunteer willing use barrier contraception ie , condom , first day dose 3 month dose IP . The female partner use contraception period . Volunteers must BMI 18 30 kg/m2 , inclusive , weigh least 50 kg . Any clinically significant disease disorder ( eg , cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine ) , may put volunteer risk participation study , influence ADME drug . Any clinically significant illness , medical/surgical procedure trauma within 4 week first administration IP . Any clinically significant abnormality clinical chemistry , hematology , urinalysis result judge Investigator . History ( personal family ) torsades de pointes , polymorphic ventricular tachycardia , long QT syndrome , sudden death Brugada syndrome , personal history sustain ( great 30 ) monomorphic ventricular tachycardia . Abnormal vital sign , 10 minute supine rest define protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy male female volunteer</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>NKTR-118</keyword>
</DOC>